Boardroom Alpha
Boardroom Alpha
ILMN · Current Report (Form 8-K) · Filed August 7, 2026

Illumina Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 7, 2026
Period
Aug 7, 2026
Ticker
ILMN
Accession
0001110803-26-000168
Boardroom Alpha · Filing insights

Illumina settles the Grail acquisition-related Delaware suit with mutual releases; no payment, dismissal sought for plaintiffs, hearing Nov 2, 2026.

About Illumina Inc
Market cap
$32.6B
1Y TSR
+106.6%
3Y TSR
+6.6%
Board grade
C
Sector
Healthcare
CEO
Jacob Thaysen
Last annual meeting: May 21, 2026 · View full Illumina Inc profile →
ilmn-20260807

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2026
ilmnlogoa19.jpg
Illumina, Inc.
(Exact name of registrant as specified in its charter)

001-35406
(Commission File Number)
Delaware33-0804655
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122
(Address of principal executive offices) (Zip code)

(858) 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueILMNThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o    



Item 8.01 Other Events.

Effective August 21, 2025, Illumina, Inc. (the “Company”) entered into a Release Agreement with the plaintiffs and all named defendants reflecting the terms of the settlement of the litigation captioned Icahn Partners LP, et al., v. Francis DeSouza, et al., C.A. No. 2023-1045-PAF (the “Action”) in the Court of Chancery of the State of Delaware (the “Court”), relating to the Company’s acquisition of GRAIL, Inc. The Defendants Francis deSouza, John Thompson, Frances Arnold, Caroline Dorsa, Robert Epstein, Scott Gottlieb, Gary Guthart, Philip Schiller and Susan Siegel (the “Defendants”) continue to deny each and all of the claims and contentions alleged by plaintiffs in the litigation and expressly deny any fault, wrongdoing or liability. The Release Agreement provides that, in exchange for mutual releases but no payment by any party, this Action shall be dismissed with prejudice as to the Plaintiffs only and without prejudice to any other Illumina stockholders. The Defendants and the Company agreed to the settlement solely to avoid the burden, expense and uncertainty of further litigation. Since the litigation is brought on behalf of the Company, the Company is named as a “Nominal Defendant”.

The litigation was settled and the parties seek to dismiss the Action, subject to the approval of the Court. The Court will hold a hearing on the proposed dismissal on November 2, 2026, at 1:30 p.m. Eastern time. A copy of the Notice of Pendency of the Action, Proposed Dismissal of the Action, and Dismissal Hearing is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1    Notice of Pendency of the Action, Proposed Dismissal of the Action, and Dismissal Hearing
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)    



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ILLUMINA, INC.
 
Date:August 7, 2026By:
/s/ JULIE COLETTI
Name:Julie Coletti
Title:Chief Legal Officer




Exhibit Index
Exhibit NumberDescription
Notice of Pendency of the Action, Proposed Dismissal of the Action, and Dismissal Hearing
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Illumina Inc (ILMN)

Reference

Frequently asked questions

When did Illumina Inc file this 8-K?
Illumina Inc (ILMN) filed this Current Report (Form 8-K) with the SEC on August 7, 2026. The accession number assigned by EDGAR is 0001110803-26-000168.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Illumina settles the Grail acquisition-related Delaware suit with mutual releases; no payment, dismissal sought for plaintiffs, hearing Nov 2, 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Illumina Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Illumina Inc has filed under CIK 1110803, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer